natgillin/translations-raw huggingface dataset:
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. 
Također su uključeni kruti oblici pripravaka kojima je namjena biti prevedeni, neposredno prije uporabe, u tekuće oblike za oralnu uporabu.
The communication method according to claim 6, wherein the mapping candidate is an EPDCCH candidate in the data region and consists of CCEs of an aggregation level, wherein the aggregation level indicates a number of CCEs that are aggregated to form one EPDCCH candidate. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 ili 8, naznačen time što je kandidat mapiranja kandidat Poboljšanog Fizičkog Kontrolnog Kanala Silazne Veze, EPDCCH, u području podataka i sastoji se od CCE-ova istog broja kao i vrijednost razine agregacije.
The method according to claim 1, wherein the composition has a pH value ranging from 5 to 7. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da mu je pH vrijednost u rasponu od 5 do 7.
The conjugate or composition for use as described in claim 14 or 1, wherein said method of treating cancer involves intra-arterial, intranasal, intraperitoneal, intravenous, intramuscular, subcutaneous, transdermal, or per os administration. 
Konjugat ili pripravak za uporabu kako je opisano u bilo kojem zahtjevu od 15 do 22, naznačen time da navedeni postupak liječenja karcinoma uključuje intraarterijalno, = intranazalno, = intraperitonealno, intravenozno, intramuskularno, potkožno, transdermalno ili per os davanje.
The formulation of anyone of claim 1 to 3, wherein the buffer is succinate at a final concentration of 1 mM to 10 mM and pH 5.8 to 6.0. 
Silikonizirani spremnik u skladu s patentnim zahtjevom 1, naznačen time što je pufer sukcinat u konačnoj koncentraciji od 1 mM do 10 mM i pH 5,8 do 6,0.
The process of claim 21 wherein the acid is hydrochloric acid. 
Postupak prema zahtjevu 11 gdje je kiselina klorovodična kiselina.
The present disclosure further relates to the host cell described wherein the antigen presenting cell is a dendritic cell. 
Stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, koja je stanica koja prezentira antigen.
Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. 
Sterilni tekući nosači korisni su u sterilnim tekućim pripravcima za parenteralnu primjenu.
The subject invention also provides a process of producing glatiramer acetate comprising the steps of: polymerizing N-carboxyanhydrides of tyrosine, alanine, Y-benzyl glutamate and N-trifluoroacetyl lysine to form protected glatiramer acetate; deprotecting protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, the solution comprises less than 0.5% of free bromine and less than 1000 ppm of metal ion impurities, to form trifluoroacetyl glatiramer acetate; 
Postupak za dobivanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da sadrži a) polimeriziranje N- karboksianhidrida od tirozina, alanina, y-benzil glutamata i trifluoracetil lizina da bi se formirao zaštićeni glatiramer acetat; b) skidanje zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, koja je otopina prethodno obrađena hvatačem broma radi uklanjanja slobodnog broma, da bi se formirao trifluoracetil glatiramer acetat;
A sliceable dairy product obtainable by the method according to claims 1 to 9. 
Mliječni proizvod koji se može rezati, naznačen time, što je dobiven metodama prema patentnim zahtjevima 1 do
Prior to 2-((1-methylpropyl)amino)ethanol addition, said suspension preferably has a temperature of between 5 and 100° C., more preferably of between 35 and 85° C., and even more preferably of between 45 and 75° C. In a preferred embodiment, said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, preferably of from 1000 to 5000 mg, and more preferably of 1 300 to 2000 mg, per liter of the aqueous phase of said suspension. 
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je prije dodavanja 2-((1- metilpropil)amino)etanola, navedena suspenzija temperature između 5 1 100%, poželjno između 35 1 85"C, poželjnije između 45 i 75%C. 11.Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu suspenziju u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene suspenzije.
The pharmaceutical composition of any of items 1 to 15, wherein said pharmaceutical composition is for the treatment of progressive tumors, late stage tumors, tumor patients with high tumor load/burden, metastatic tumors, or tumor patients with a CEA serum concentration higher than 100 ng/ml. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je navedeni farmaceutski pripravak namijenjen liječenju uznapredovalih tumora, kasnog stadija tumora, tumorskih pacijenata visoko opterećenih tumorom, metastazirajućih tumora ili tumorskih pacijenata s koncentracijom CEA u serumu višom od 100 ng/ml.
A compound of formula (I) 
Spoj s formulom (I) pri čemu
According to the same publication WO 2004/026497 it is also provided the possibility of withdrawing sheets after the first roughing step, but without a controlled cooling system, as required for producing high-quality sheets. 
Prema istoj publikaciji WO 2004/026497 također se daje mogućnost povlačenja limova nakon prvog koraka grube obrade, ali bez kontroliranog sustava hlađenja, što je potrebno za proizvodnju limova visoke kvalitete.
55 wt% of the at least one mineral material particles have a particle size of < 1 µm after step c). 
55 wt% čestica barem jednog mineralnog materijala ima veličinu čestica od < 2 um nakon koraka c).
Optionally the spraying nozzles may have a dynamically changeable orientation. According to some embodiments of the present invention, applying the water-free silane-based liquid may be done by brushing or rolling the water-free silane-based liquid to the profiled surface. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se nanošenje navedene bezvodne tekućine na bazi silana provodi četkanjem ili valjanjem navedene bezvodne tekućine na bazi silana na profiliranu površinu.
Removal of solvent gives a viscous liquid which is purified by column chromatography (silica gel 230-400 mesh, mobile phase n-hexane:ethyl acetate 7:3) to get 3-(4-octylbenzylamino)cyclopentane-1,1-dicarboxylic acid diethyl ester as a colourless viscous liquid. 
Uklanjanjem otapala dobije se viskozna tekućina, koju se pročisti kromatografijom na stupcu (silikagel veličine čestica 0,066-0,037 mm (230-400 mesh), pokretna faza je n-heksan/etil-acetat 7:3) kako bi se dobilo dietilni ester 3-(4- oktilbenzilamino)ciklopentan-1,1-dikarboksilne kiseline u obliku bezbojne viskozne tekućine.
is hydrogen, halo, hydroxy, trifluoromethyl, alkoxy, alkyl, alkenyl, alkynyl, carbocyclic, alkylcarbocyclic, alkylheterocyclic, heterocyclic, or —R9—OR10, wherein R9 is a covalent bond or alkyl, and R10 is hydrogen, alkyl, C-amido or acyl; or R2 together with R3 and the atoms to which they are attached form a carbocyclic ring with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members with at least one heteroatom selected from oxygen or nitrogen; 
je kovalentna veza ili alkilen, i je vodik, alkil, C-amido ili acil; ili zajedno s R3 i atomima na koje su vezani tvori karbociklički prsten s 5 do 7 članova prstena ili heterociklički prsten s 4 do 8 članova prstena s najmanje jednim heteroatomom kojeg se bira između kisika ili dušika;
the mixture SR, RS, RR and SS of the epoxide 1 is reacted with a secondary amine of RR3NH type, wherein R has the meaning seen in the foregoing, and R3 is a benzyl group, possibly mono- or disubstituted with a group selected from: halogen, nitro, a C1-C4 alkyl chain, CF3, CHF2, an OR2 group, where R2 is a hydrogen, a C1-C4 alkyl, to obtain a mixture of the four compounds 12, 13, 4 and 5, from which the pair 12/13 is separated from the pair 4/5; eliminating the group R3, to obtain a mixture of compounds 2/3 
Postupak prema patentnom zahtjevu 1, naznačen time, da je djelomična alternativa točki a. sljedeći korak: m. smjesa SR, RS, RR i SS epoksida 1 reagira sa sekundarnim aminom RR3NH tipa, pri čemu R ima značenje koje je gore navedeno, a Rs je benzilna skupina, eventualno mono-ili disupstituirana sa skupinom odabranom iz skupine: halogena, nitro, C;-Cy-alkilnog lanca, CF3, CHF>, OR> skupine, gdje je R» vodik, C,-C, alkil, čime se dobiva smjesa od četiri spoje 12, 13, 415, od kojih je par 12/3 odvojen od para 4/5;
is reacted in a solvent with sodium hydroxide or aqueous sodium hydroxide solution or a sodium salt, if appropriate with addition of a base. 
(lb) reagira u otapalu s natrijevim hidroksidom ili vodenom otopinom natrijevog hidroksida ili natrijevom soli, ako je prikladno uz dodavanje baze.
coupling compound (1) and compound (2) under amide bond-forming conditions and deprotecting the product to form compound (3): where P is an amino-protecting group; 
sprezanje spoja (1) i spoja (2) u uvjetima za nastanak amidne veze te skidanje zaštite, čime se dobiva spoj (3): [image] pri čemu je P zaštitna amino skupina;
150 mg of product were obtained which were purified on silica gel, eluting with AcOEt/MeOH 1:1. 
Dobiveno je 150 mg produkta koji je pročišćen na silikagelu, ispiranjem s AcOEY#MeOH 1:1.
The compound or mixture of compounds for use according to claim 10, wherein the oral form is an oral solution or an oral suspension; or the oral form is selected from the group consisting of tablets, capsules, pills, and granules. 
Spoj, ili smjesa spojeva, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je oralni oblik doziranja oralna otopina ili oralna suspenzija; ili oralni oblik doziranja se bira iz skupine koju čine tablete, kapsule, pilule, te granule.
The building element according to claim 3, wherein said building element is substantially symmetrical along the wooden core. 
Zidna ploča sukladno zahtjevu 2, pri čemu je ploča (4) supstancijalno simetrična duž drvenog središnjeg elementa (41).
The process according to claim 18, wherein the temperature in the first and/or the second insulator are changed according to each process step. 
Postupak prema jednom od Zahtjeva 18 do 25, naznačen time da se temperatura u prvom i/ili drugom izolatoru mijenja ovisno u koraku postupka koji je u tijeku.
successively routing each one of said at plurality of ducts/cables to its endpoint; said endpoint being one of said at least one splicing point (F) or one of said final destinations connected through one of said branches, according to said network layout; 
- uzastopnog usmjeravanja svakog od navedenih pluraliteta vodova / kabela na krajnju točku; navedena krajnja točka je jedna od navedene najmanje jedne točke spajanja (F) ili je jedno od navedenih konačnih odredišta povezano kroz jednu od navedenih grana, prema navedenom mrežnom rasporedu;
In a further aspect of the invention a solid oral extended release pharmaceutical dosage form is provided that is bioequivalent to the commercial product Palladone™ as sold in the United States in 2005. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja kada je ispitivan u komparativnoj kliničkoj studiji je bioekvivalentan sa komercijalnim proizvodom OxyContinTM,
A compound of claim 2, wherein A is a 6-membered heterocyclic ring, which may contain 0-3 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)Ra, -SO2Ra, arylalkyl, -(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; each R2 and R3 is independently hydrogen, C1-C6alkyl, substituted C1-C6alkyl, halo, hydroxyl, amide, carboxylic acid or C1-C4alkoxy; 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je A 6-eročlani heterociklički prsten, koji može sadržavati 0-3 dvostruke veze i može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C;-Cgalkil, supstituirani C;-Cgalkil, C3-Czcikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R., arilalkil, (C,-Csalkiljariloksi, aril, heteroaril i Ci-Cu,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-C;cikloalkil; svaki R> i Rz je neovisno vodik, C,-Cgalkil, supstituirani C,-Cgalkil, halogen, hidroksil, amid, karboksilna kiselina ili Ci-C,alkoksi;
a rear end of the flexible fiber-optic bundle is provided with a rear end lens group for converging and directing the light to the light transmitting cylinder. The system of claim 2, wherein the light conduction device is the light conduction cylinder having a front end being vertically fixed; the convex-concave lens group coupled to the light conduction cylinder is disposed in the housing of the light collector; the pitch main shaft and the azimuthal main shaft connected to the housing of the light collector are both hollow cylinders having inner walls provided with reflective films, and the optical paths in the hollow cylinders of the pitch main shaft and the azimuthal main shaft communicate with each other; 
Sustav prema zahtjevu 2, naznačen time što uređaj za provođenje svjetlosti je savitljivi svjetlovodni snop, a njegov prednji kraj je okomito pričvršćen na kućište svjetlosnog kolektora; fokus konveksne leće donjeg sloja skupine konveksnih leća za skupljanje svjetlosti pada na stranu savitljivog svjetlovodnog snopa koja prima svjetlost; i stražnji kraj savitljivog svjetlovodnog snopa opremljen je sa skupinom leća stražnjeg kraja za konvergiranje i usmjeravanje svjetla na cilindar koji odašilje svjetlost.
The composition of claim 3, wherein the mixture M consists essentially of: 
Tkanina u skladu s patentnim zahtjevom 4, pri čemu smjesa M sadrži:
A compound according to claim 26 wherein R8 is hydroxy, methoxy, methoxyphenyl, NH2, NHMe, NMe2, NHCO2tBu, NMeCO2tBu, CO2H, CONHMe, RG or RH, the last two of which are optionally substituted with one or more R9 groups. 
Spoj u skladu s patentnim zahtjevom 26, naznačen time što R? je hidroksi, metoksi, metoksifenil, NH,, NHMe, NMe,, NHCOZBu, NMeCO;Bu, CO,H, CONHMe, R* ili RF, od kojih su potonja dva izborno supstituirana s jednom ili više skupina R".
The integrated rotary mixer and disperser head according to claim 18, wherein the plurality of elongated slots extends in a generally axial direction of the mixing chamber. 
Integrirana rotacijska miješalica 1 glava raspršivača (1) prema 18. tvrdnji gdje se mnoštvo izduženih proreza proteže u općenito aksijalnom smjeru komore za miješanje (4).
A compound of formula I, 
Spoj prema formuli I, mo Mj E
combining a compound of claim 1 with a pharmaceutical excipient to form a pharmaceutical composition; 
(a) kombiniranje spoja u skladu s patentnim zahtjevom 1 s farmaceutskim pomoćnim sredstvom da se dobije farmaceutski pripravak;
The mixture was shaken under H2 at 55 psi for 4 h, filtered over celite and concentrated to give the title compound as a yellow solid (0.4021 g, 98% yield). 
Smjesa je mućkana pod H> na 55 psi 4 sata, filtrirana preko celita i koncentrirana da bi se dobio spoj iz naslova kao žuta čvrsta supstanca (0.4021 g, 98% prinos).
List of reference numeral: 1 
Popis referentnih oznaka: 1
The compound or a salt thereof, or a solvate of these according to claim 1, wherein R1 is a methyl group. 
Spoj ili njegova sol ili solvat u skladu s patentnim zahtjevom 1, naznačen time, da je R1 metilna skupina.
The composition comprises a polyfunctional resin, a fatty acid or derivative thereof and optionally a curing agent and/or one or more additives, 
- < polifunkcionalnu smolu, masnu kiselinu ili njezin derivat i prema potrebi sredstvo za umreživanje i/ili jedan ili više dodataka, pri čemu smola ima funkcionalne skupine koje mogu reagirati s karboksilnim ili kiselinskim skupinama masne kiseline ili njezinog derivata.
The process of any of the previous claims, wherein the process further comprises the steps of: measuring a parameter value of the remineralized water, wherein the parameter is selected from the group comprising alkalinity, total hardness, conductivity, calcium concentration, pH, CO2 concentration, total dissolved solids, and turbidity of the remineralized water, 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da postupak nadalje sadrži korake: d) mjerenje parametarske vrijednosti remineralizirane vode, pri čemu je parametar odabran i skupine koju čine alkalnost, ukupna tvrdoća, vodljivost, koncentracija kalcija, pH, koncentracija CO2, ukupne otopljene krute tvari, te zamućenost remineralizirane vode,
The bispecific antibody or antibody fragment or the pharmaceutical composition according to claim 13, wherein the disease is selected from the group consisting of: a TH2-mediated disease, an IL-4 and/or IL-13 mediated disease, an allergic disease, asthma, cancer, an autoimmune disease, a disease associated with abnormal production of IL-4 and/or IL-13, scleroderma and idiopathic pulmonary fibrosis. 
Humanizirano bispecifično protutijelo za uporabu prema zahtjevu 10, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, skleroderma i idiopatska plućna fibroza.
The compound of claim 1, wherein the compound is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što ga se bira iz skupine koju čine:
A compound of formula (I) according to embodiment 13 wherein wherein R2 is arylalkyl or heteroarylalkyl, substituted with C1-3alkyl, hydroxyl, alkoxy, nitrile, heterocycle or ester and wherein R1 and R3 are as specified above. 
Spoj formulom (1) prema zahtjevu 1 naznačen time što R, je arilalkil ili heteroarilalkil, supstituiran s C;salkilom, hidroksilom, alkoksi, nitrilom, heterociklom ili esterom i pri čemu R, i Rs su kao što je gore navedeno.
5% to 30% by weight of a compound of formula (1) or a pharmaceutically acceptable salt thereof; 
do 30 masenih % spoja formule (1) ili njegove farmaceutski prihvatljive soli;
A fuel gas supply system of a vessel for supplying fuel gas from an LNG tank, which stores LNG as fuel gas, to a high-pressure gas injection engine, comprising: 
Sustav dobave pogonskog plina za brod osim za tanker za LNG za dobavu pogonskog plina do visokotlačnog plinskog injekcijskog motora za brod, te sustav dobave pogonskog plina sadrži: spremnik LNG (1);
The plates were then washed and the colour reaction was developed by adding 125 ul/well OPD substrate solution. The reaction was stopped by adding 125 ul/well of 4N HCl. 
Pločice su potom isprane i obojena rekacija je razvijena dodatkom 125 ul/bunariću otopine OPD supstrata, Rekacija je zaustavljena dodatkom 4N HCl1-a, 125 ul/bunariću.
Obviously, conduit 14 and any connectors, whether conduit 14 is a unitary member or in segments or pieces, are fluid tight from bottle 20 through nozzle 12. 
Očigledno je da su cjevovod 1 svi priključci, bilo da je cjevovod 14 jedan jedinstveni element ili se sastoji od segmenata ili dijelova, hermetički povezani od boce 20 do mlaznice 12.
Alternatively, the metallated species derived from compounds XIII may be quenched with compounds of formula XV according to the procedure of Marchand et al. 
Alternativno, metalizirana vrata derivirana iz spojeva XIII može biti ugašena spojevima formule XV na način kao u Marchand i sur.
or saline and the recording was continued for 60 min. 
bilo fiziološku otopinu i bilježenje se nastavi tijekom 60 minuta.
The method of claim 1, wherein the assaying comprises assaying a percentage decrease in the human subject's platelet number from the human subject's platelet number prior to telomerase inhibition therapy. The method of claim 3, wherein the assaying comprises multiplying the average or median telomere length by a coefficient to arrive at a telomere length component; 
utvrđivanje srednje vrijednosti ili medijana dužine telomere u biološkom uzorku koji sadrži stanice dobivene iz subjekta koji je sisavac prije ili u vrijeme liječenja terapijom inhibicije telomeraze i množenje srednje vrijednosti ili medijana dužine telomere koeficijentom kako bi se dobilo komponentu dužine telomere; množenje namjeravane doze liječenja koeficijentom da se dobije komponenta doze; i
In embodiments as described above the tablet may be formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C, at least about 62 °C, at least about 68 °C, at least about 70 °C, at least about 72 °C or at least about 75 °C for a time period of at least about 1 minute, at least about 5 minutes or at least about 15 minutes. 
Oblik doziranja sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 12, naznačen time da je u obliku tablete oblikovane pomoću direktnog prešanja pripravka, te koja je stvrdnuta barem podvrgavanjem navedene tablete temperaturi od najmanje oko 60?%C ili najmanje oko 62*C u vremenskom periodu od najmanje oko 1 minute, poželjno najmanje oko 5 minuta ili najmanje oko 15 minuta.
Conditional uplink timing alignment in a mobile station device of a radio communication system 
(54) Naziv izuma: USKLAĐIVANJE VREMENA U RADIO KOMUNIKACIJSKOM SUSTAVU
A method of targeting a molecule, composition or a complex to a site characterized by the presence of an a2B1 integrin ligand, the method comprising attaching or binding the molecule, composition or a complex to the humanized anti-a2 integrin antibody of claim 1. 
Metoda ciljanja molekule, oblika ili kompleksa prema mjestu naznačenim prisutnošću 2B1 integrin liganda, metoda obuhvaća spajanje ili vezanje molekule, oblika ili kompleksa za humanizirano anti-a2 integrin protutijelo prema zahtjevu 1.
ethers such as diethyl ether, methyl tert-butyl ether, and tetrahydrofuran, especially methyl tert-butyl ether, may be added if necessary or desired. 
eteri kao što je dietil eter, metil terc-butil eter, može se dodati ako je neophodno ili se želi.
The compounds of the present invention are capable of being administered in unit dose forms, wherein the term "unit dose" means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter. 
Spojeve prema ovom izumu može se primijeniti u oblicima jedinica doze, gdje termin "jedinica doze" znači jedna doza koju se može primijeniti na pacijentu, te s kojom se lako rukuje i lako se pakira, a ostaje u obliku fizički i kemijski stabilne jedinice doze koja sadrži bilo sam aktivni spoj, ili je u obliku farmaceutski prihvatljivog pripravka, kao što je opisano niže u ovoj specifikaciji.
Combined organic extracts were dried over Na2SO4 and concentrated to give compound 6f (0.12 g). 
Pomiješane organske ekstrakte osuši se preko Na»SOxy, te koncentrira kako bi se dobilo spoj 6f (0,12 g).
Manufacturing of the capules: 
Broj objave europskog patenta:
R27', R28', R29' and R30' are absent, or R27', R28', R29' and R30' are H under the condition that R28, R29 and R30 are H and that R27 is selected from H, chloro or fluoro; and the two bonds represented by the dotted lines in formula Ig-4 are both absent, or both present under the condition that R27', R28', R29' and R30' are absent; and 
’, R28’, R29’ i R30’ su odsutni, ili R27’, R28’, R29’ i R30’ su H pod uvjetom da R28, R29 i R30 su H i da R27 je odabran od H, kloro ili fluoro; i dvije poveznice predstavljene isprekidanim linijama u formuli Ig-4 su obje odsutne, ili su obje prisutne pod uvjetom da R27’, R28’, R29’ i R30’ su odsutni; i
sealing member/sealing material 9 
element za nepropusno zatvaranje/materijal za brtvljenje 9